Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons-Reference-Cited by-同舟云学术

Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons

Published:2022-06-14 Issue:3 Volume:76 Page:e537-e539
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Ranganath Nischal¹,O’Horo John C¹²,Challener Douglas W¹,Tulledge-Scheitel Sidna M³,Pike Marsha L⁴,O’Brien Michael⁵,Razonable Raymund R¹^ORCID,Shah Aditya¹^ORCID

Affiliation:

1. Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic , Rochester, Minnesota , USA

2. Division of Pulmonary and Critical Care Medicine, Mayo Clinic , Rochester, Minnesota , USA

3. Division of Community Internal Medicine, Mayo Clinic , Rochester, Minnesota , USA

4. Department of Nursing, Mayo Clinic , Rochester, Minnesota , USA

5. Department of Pharmacy, Mayo Clinic , Rochester, Minnesota , USA

Abstract

Abstract In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19–directed therapy.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac481/46353345/ciac481.pdf

Reference8 articles.

1. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19;Hammond;N Engl J Med,2022

2. Rapid Relapse of Symptomatic SARS-CoV-2 Infection Following Early Suppression with Nirmatrelvir/Ritonavir

3. A Framework for outpatient infusion of antispike monoclonal antibodies to high-risk patients with mild-to-moderate coronavirus disease-19: the mayo clinic model;Razonable;Mayo Clin Proc,2021

4. Clinical prioritization of antispike monoclonal antibody treatment of mild to moderate COVID-19;Razonable;Mayo Clin Proc,2022

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19;BMC Infectious Diseases;2024-09-12

2. An overview of the development of pharmacotherapeutics targeting SARS-CoV-2;Drug Discovery Today;2024-09

3. Antiviral therapy for COVID-19;COVID-19: An Update;2024-09-01

4. Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro;The Journal of Infectious Diseases;2024-08-12

5. Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis;Tungs' Medical Journal;2024-08-08